Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Acadia Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals focuses on neuroscience and provides FDA-approved treatments for conditions such as Parkinson's disease psychosis and Rett syndrome, while developing novel therapies for neurological disorders.

Metric
Company Name	Acadia Pharmaceuticals Inc.
Symbol	ACAD
MSH ID	COM:ACADIA
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	620
Website	acadia.com
LinkedIn
Founders

Metric
Market Cap	2.72B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	726.44M
Revenue (LTM)
Revenue (NTM)
Gross Profit	680.71M
EBITDA	-67.83M
Operating Income	-73.38M
Net Income	-61.29M
EPS	-0.37
Diluted EPS	-0.37
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.94
Operating Profit Margin	0.03
EBITDA Margin	-0.09
Net Profit Margin	0.03
Return on Equity	0.07
Return on Assets	0.03
Return on Capital Employed	0.04

COM:ACADIA

Acadia Pharmaceuticals

Last Close

16.18

22/11 21:00

Market Cap

2.83B

Beta: -

Volume Today

1.40M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-27.70
P/B Ratio	11.38
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.09
EV Multiple	1.30K

Metric
Days Sales Outstanding	54.61
Days Payables Outstanding	171.75
Days Inventory Outstanding	359.27
Operating Cycle	404.16
Cash Conversion Cycle	301.03
Asset Turnover	0.97

Metric
Operating Cash Flow	16.70M
Free Cash Flow	-23.35M
Cash Flow to Debt	1.40
Operating Cash Flow/Sales	0.09
Free Cash Flow Yield	-0.02

Metric
Cash & Equivalents	188.66M
Accounts Receivable	-39.27M
Inventory	35.82M
Goodwill
Debt to Capitalization	0.12
Debt to Assets	0.08
Current Ratio	2.38
Quick Ratio	2.13

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.10
R&D to Revenue	0.57
SG&A to Revenue	0.15